Keyphrases
Tolerability
100%
Gemcitabine Plus Cisplatin
100%
Urothelial Cancer
100%
Elderly People
100%
Cancer in the Elderly
100%
Gemcitabine
66%
Neoadjuvant Setting
50%
Febrile Neutropenia
33%
Dosing Regimen
16%
Study Support
16%
Cisplatin
16%
Standard of Care
16%
Metastatic Urothelial Cancer
16%
Renal Disease
16%
Treatment Regimen
16%
Serum Creatinine
16%
Hematotoxicity
16%
Treatment Delay
16%
Dose Adjustment
16%
Primary Prophylaxis
16%
Optimal Schedule
16%
Optimal Dose
16%
Growth Factor Support
16%
Pharmacology, Toxicology and Pharmaceutical Science
Tolerability
100%
Cisplatin
100%
Malignant Neoplasm
100%
Gemcitabine
100%
Febrile Neutropenia
20%
Retrospective Study
10%
Growth Factor
10%
Creatinine
10%
Isoprenaline
10%